(NASDAQ: CRNX) Crinetics Pharmaceuticals's forecast annual revenue growth rate of 133.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Crinetics Pharmaceuticals's revenue in 2023 is $4,722,000.On average, 5 Wall Street analysts forecast CRNX's revenue for 2023 to be $271,872,976, with the lowest CRNX revenue forecast at $247,157,251, and the highest CRNX revenue forecast at $309,948,552. On average, 2 Wall Street analysts forecast CRNX's revenue for 2024 to be $3,486,253,223, with the lowest CRNX revenue forecast at $166,998,143, and the highest CRNX revenue forecast at $6,805,508,303.
In 2025, CRNX is forecast to generate $3,703,350,808 in revenue, with the lowest revenue forecast at $500,994,428 and the highest revenue forecast at $12,430,673,735.